BGB-53038
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGB-53038, covering 2026-03-18 to 2026-03-18. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification [Phase 1]